Tagged with R

France France may have ceded Europe’s top spot for the sheer number of clinical trial starts to Spain in 2023, but it remains one of Europe’s most strategically valuable destinations for complex, high-science clinical research. In oncology and rare diseases clinical R&D especially, France punches well above its weight, supported by…

France Valued fifth globally in terms of overall revenues and enjoying year-on-year growth rates exceeding five percent, the French pharma market is undeniably one of the great global life science powerhouses, playing host to virtually all top-tier, big-brand biopharma. Yet alongside its well-forged reputation for sophisticated healthcare infrastructure, manufacturing excellence, and…

France How can mid-sized European pharmaceutical companies, which lack the scale of both Big Pharma and the major generics players, compete in a country like France? Norgine – a specialist player which turns over around EUR 600 million annually – seems to have hit upon a solution: continuous adaptation.   “What…

France When Marc de Garidel joined AbiVax as CEO in 2023, the firm had very recently teetered on the brink of bankruptcy. Now, less than three short years later, he leads the hottest prospect in European biotech, with a potentially market-leading drug for inflammatory bowel disease nearing regulatory approval. de Garidel…

Global Ahead of this year’s International Women’s Day on March 8th, Unjela Kaleem highlights the disproportionate impact of cancer on women, especially those in developing countries. Kaleem – drawing on 20+ years of experience in healthcare strategic communications – argues that celebrating women’s economic empowerment while ignoring the cancers that take…

Hong Kong From factory automation in Silicon Valley to scalable service robotics embedded in daily care, Roy Long Hei’s journey with Robocore reflects a disciplined belief that technology must prove itself in real operating environments. What begins as a distribution-first strategy in Hong Kong evolved into full ownership of the TEMI®  platform…

UAE Global advances in rare blood disorders increasingly hinge on where evidence is generated, how patients are followed, and whether innovation reaches beyond a limited few. Khaled Musallam describes how clinical reality at Burjeel informs international research, trial design, and guideline development, while pressing for models that balance scientific ambition with…

Taiwan ImmunAdd’s Dr Pi-Hui Liang discusses her transition from academic research to entrepreneurship, driven by the critical shortage of commercially available vaccine adjuvants. With a proprietary saponin-based platform addressing supply chain constraints and toxicity limitations of existing adjuvants, ImmunAdd aims to democratise access to advanced immunological tools whilst developing its own…

MEA CTI EMEA Managing Director Alaa Assem is a physician, ophthalmologist and MBA holder with over 30 years of experience in pharma and clinical research organisations. Since joining CTI, he has strengthened the company’s presence in the Middle East, focusing on rare disease, gene and cell therapy, oncology, and transplantation. CTI…

Taiwan Dr Ethan Shen moves comfortably between the clinic, the laboratory, and capital markets, and this conversation reflects that rare vantage point. He explains how YD Bio is built not as a single-asset biotech, but as an integrated platform designed to connect diagnostics, data, and advanced therapies with real clinical execution.…

Taiwan Dr John Chang, Chief Executive Officer of the Formosa Cancer Foundation and a distinguished medical oncologist at Chang Gung Memorial Hospital, provides a comprehensive strategic analysis of Taiwan’s oncology landscape. He delineates the evolution of precision medicine, the economic intricacies of national health reimbursement, and the critical role of patient…

Taiwan Jerry Cheng is general manager for Illumina across Taiwan, Hong Kong, and Macau, steering the company’s expansion in three strategically significant genomics markets. With over two decades of pharmaceutical industry experience, including pioneering biomarker-driven oncology therapeutics, Cheng now orchestrates Illumina’s transition from research instrumentation to clinical implementation. His mandate encompasses…